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Abstract 
Introduction: Inhaled antibiotics may improve symptom scores but it is not known which specific 
symptoms improve with therapy. Item-level analysis of questionnaire data may allow us to identify which 
specific symptoms respond best to treatment.  
Methods: Post-hoc analysis of the AIR-BX1 and 2 trials of inhaled aztreonam vs placebo in bronchiectasis. 
Individual items from the quality of life bronchiectasis respiratory symptom scale (QOL-B) were extracted, 
as representing severity of 9 distinct symptoms. Generalized linear models were used to evaluate changes 
in symptoms with treatment vs placebo from baseline to end of first on treatment cycle and mixed models 
used to evaluate changes across the full 16 week trial.  
Results: Aztreonam improved cough (difference 0.22; 95%CI 0.08-0.37,p=0.002), sputum production 
(0.30; 95%CI 0.15-0.44,p<0.0001) and sputum colour (0.29; 95%CI 0.15-0.43p<0.0001) vs placebo 
equating to a 20% improvement in cough and 25% improvement in sputum production and colour 
respectively. Similar results were observed for cough, sputum production and sputum purulence across the 
trial duration (all p<0.05). Patients with higher sputum production and sputum colour scores had a greater 
response on the overall QOL-B (difference 4.82; 95%CI 1.12-8.53,p=0.011) for sputum production and 
5.02; 95%CI 1.19-8.86,p=0.01 for sputum colour. In contrast, treating patients who had lower levels of 
bronchitic symptoms resulted in shorter time to next exacerbations (HR 1.83; 95%CI 1.02-3.28,p=0.042). 
Conclusion: Baseline bronchitic symptoms predict response to inhaled aztreonam in bronchiectasis. More 
sensitive tools to measure bronchitic symptoms may be useful to enrich for inhaled antibiotic responders 
and to evaluate patient response to treatment.  
  
Introduction 
Bronchiectasis significantly impacts upon patients quality of life, affecting physical, emotional and social 
aspects of wellbeing.(1,2) Disease progression is driven by recurrent exacerbations which are associated 
with reduced lung function and in severe cases can lead to respiratory failure and even death (1,3–5). 
Exacerbation frequency and long term mortality are increased in patients with chronic airway infection with 
bacterial pathogens.(6) Pseudomonas aeruginosa is the most common organism isolated from patients 
sputum worldwide and is strongly associated with worse quality of life, lower lung function, higher risk of 
hospitalisation and increased mortality rates.(7,8) This high burden of disease highlights the need to develop 
evidence based therapies that can reduce the burden of bacterial infection. Inhaled antibiotics deliver high 
concentrations of antibiotic to the site of infection resulting in marked reductions in airway bacterial load 
in patients with bronchiectasis.(9) It has been challenging, however, to clearly demonstrate that these 
reductions in bacterial burden translate into clinical benefits. A recent meta-analysis of 16 trials including 
2597 patients with bronchiectasis showed strong antimicrobial efficacy with a pooled reduction of 2.3 log 
units in colony forming units, but this translated into only modest reductions in exacerbation frequency 
(rate ratio 0.8; 95% CI 0.67 to 0.97) and no clinically significant improvement in symptoms.(9) Despite 
these inconclusive data, inhaled antibiotics are still frequently used “off-label” with patient and clinician 
perception that they provide benefits.(10) 
A possible explanation for this difference between “real life” and randomized studies is the tools used to 
measure symptoms.(11) The number of validated health related quality of life (HRQOL) tools used in 
bronchiectasis trials is limited, and the quality of life bronchiectasis questionnaire (QOL-B) is the only 
disease-specific tool that has been tested in multiple randomized trials.(11) Its respiratory symptom scale 
consists of 9 questions asking about congestion, cough, sputum production, sputum colour, shortness of 
breath, wheezing, chest pain, shortness of breath while talking, and nocturnal cough.  Each of these 
symptoms is potentially important to patients with bronchiectasis, and each symptom is likely to be 
associated with severity of disease and morbidity.(2,11) It is less certain, however, that a specific treatment 
would be expected to improve all of these symptoms. 
Extensive prior research suggests that elevated bacterial load induces neutrophil inflammation including 
the release of myeloperoxidase which causes sputum purulence and neutrophil elastase which is a key 
mediator of cough and sputum production through direct stimulation of mucin production from epithelial 
cells and impairment of mucociliary clearance.(12–14) Inhaled antibiotic treatment has been shown to 
rapidly reduce neutrophilic inflammation and therefore might be expected to also reduce cough, sputum 
production and sputum purulence.(15) In contrast, breathlessness is associated with airflow obstruction, 
emphysema, cardiovascular fitness, anaemia conditioning and neuromuscular function, all of which may 
not be immediately modified with inhaled antibiotics.(3,16) In the recent meta-analysis inhaled antibiotics 
reduced, rather than improved FEV1.(9)   
We therefore hypothesised that by examining the effect of an inhaled antibiotic on individual symptom 
responses we would observe that inhaled antibiotics improve cough, sputum and sputum purulence while 
having much less effect on other symptoms. To investigate this, we used itemised QOL-B data collected 




AIR-BX1 and AIR-BX2 were identical, double-blind, multicentre, randomised, placebo-controlled, phase 
3 trials consisting of two, 4-week on 4-week off, treatment cycles. Patients received either inhaled 
aztreonam lysine (AZLI) 75mg or placebo three times daily. Eligibility criteria has previously been 
published (17). This analysis only included patients who gave additional consent for future exploratory 
analysis of their data and we have previously published that there were no significant differences in 
characteristics between the original trial cohort and those who consented to future analysis (18).  
The primary endpoint used in the AIRBX studies was change in quality of life bronchiectasis respiratory 
symptoms score (QOLB-RSS) at week 4, the end of the first on-treatment cycle.(11) Secondary endpoints 
included the change in QOLB-RSS at week 12. The minimal important difference for the QOL-B-RSS as 
a whole is an 8-point change.(11) 
Time to first protocol-defined exacerbation by week 16 was a secondary endpoint of special interest in the 
AIRBX studies. The exacerbation definition used was as follows; acute worsening of respiratory disease 
meeting ⩾3 major criteria (or two major and at least two minor). Major criteria were increased sputum 
production, change in sputum colour, dyspnoea and cough while minor criteria were fever (>38°C) at clinic 
visit, increased malaise or fatigue, FEV1 (L) or FVC decreased by more than 10% from baseline, and new 
or increased haemoptysis.(17) 
Item level analysis 
The 9 items of the QOLB-RSS are shown below in Table 1. The items are answered with a one week recall 
period and have four options. Lower scores reflect poor quality of life from increased respiratory symptoms 
while high scores show lesser impact. For individual item level analysis, the responses (table 1) were 
converted into numerical values for analysis with 1 representing the most severe response (a lot/always) 
and 4 representing the least severe response (not at all/never). For sputum colour, there are 6 possible 
responses in the QOL-B. ‘Brownish-dark’ and ‘green with traces of blood’ are both rated the same severity 
and no score is given to the answer ‘Don’t know’. 
Question Responses 
29. Have you felt congestion (fullness) in 
your chest? 
A lot        A moderate 
amount      
A little     Not at all 
30. Have you been coughing during the 
day 
A lot A moderate 
amount 
A little     Not at all 
31. Have you had to cough up sputum? A lot A moderate 
amount 
A little     Not at all 
32. Has your sputum been mostly 
 
Green with 
traces of blood 
or       
Brownish- dark     
Yellowish-





33. Have you had shortness of breath 
when being active, such as when doing 
housework or gardening? 
Always Often Sometimes Never 
34. Have you had wheezing? Always Often Sometimes Never 
35. Have you had chest pain? Always Often Sometimes Never 
36. Have you had shortness of breath 
when talking? 
Always Often Sometimes Never 
37. Have you woken during the night 
because you were coughing? 
Always Often Sometimes Never 
Table 1. Individual items completing the quality of life bronchiectasis respiratory symptom domain. These 
questions form the last domain of QOLB and are numbers 29 – 37. 
 
Statistical analysis 
Changes from baseline to visit 4 (end of first on-treatment period) 
To test the hypothesis that AZLI treatment would improve specific symptoms linked to bacterial load we 
analysed the effect of AZLI treatment vs placebo on each individual item within the QOL-B RSS 
questionnaire as listed in table 1. Analysis was conducted using the intention to treat principle. Studies were 
initially evaluated separately (AIR-BX1 and AIR-BX2) and then pooled. The second hypothesis was that 
patients with more cough, sputum production and sputum purulence at baseline would experience a superior 
response to inhaled antibiotic treatment. In the analysis of change from baseline to visit 4 we used a 
generalized linear model with the change in each individual symptom domain as the outcome in each of the 
4 baseline severity categories. High symptom patients were those answering 1-2 per item and low symptom 
patients were those answering 3-4.  
 
Repeated measures analysis across the entire study duration 
For analysis of whether baseline symptoms predicted QOL-B RSS response across the entire trial duration 
we used a mixed effects model. The full model for each question contained the four treatment terms:  1) an 
immediate effect of treatment (visits 3,4 and 6 while patients were receiving either AZLI or placebo) and 
2) a longer term (study duration incorporating data from visits when off-drug) placebo effect affecting both 
arms equally, as well as 3) an additional short-term and 4) a longer-term drug effect that only affected the 
patients receiving AZLI. For each analysis data are presented for full models, which contain all 4 treatment 
parameters and for a best model which, where all available parameters were statistically significant. The 
data from the two trials was combined, and an intercept plus a single common drift term included along 
with individual as a random effect. Interactions were included for baseline symptoms and AZLI response. 
Model selection and averaging was done by Akaike information criterion (AICc).  
To evaluate treatment effects of individual symptoms across the entire study duration we used a similar 
mixed effects model with the response to each individual question as the outcome. As there are only four 
possible answers to each question, uncertainties around these models’ estimates were generated by 
bootstrap resampling the data. The data from the two trials was pooled for simplicity and because 
preliminary analyses identified no differences between the response in the two trials. 15 sub-models were 
fitted, containing each combination of the four treatment terms. Terms were considered statistically 
significant where their 95% confidence interval from bootstrapping did not cross zero. The model for each 
question, among those for which all parameters were statistically significant, that contained the largest 
number of parameters was considered best. 
For interpretation of results we considered a p-value of less than 0.05 as statistically significant. In view of 
the multiple comparisons performed we also applied a Holm-Bonferroni correction to the primary results. 




A combined 440 participants were included in the analysis. Table 2 shows the demographics for 
participants. More detailed patient characteristics have been previously published demonstrating no 
significant differences between the patient characteristics in AIR-BX1 and 2.(18) Patients had an average 
age of 64 years. Patients were predominantly female (70%) with moderate FEV1 impairment. 131 protocol 
defined exacerbations were recorded throughout the study although 70% of participants did not experience 





median (IQR) Range 
Sample size 440  
Female Sex  306 (69.5%)  
Age  63.8 (12.9) 18 to 87 
FEV1 %predicted 62.3 (20.4) 18.0 to 115.5 
QOLB-RSS score  55.9 (18.5) 0 to 96 
- QOLB-RSS score change to visit 4 (n=385)  6.84 (17.49) -50.9 to 77.8 
Protocol defined exacerbations during study period  0 (0-1) 0 to 3 
1 exacerbation  110 (24.8%)  
>1 exacerbation  21 (4.8%)  
Table 2. Combined AIR-BX1 and AIR-BX2 participant characteristics.  
 
Treatment response for individual symptoms 
First we examined the original trial primary endpoint which was change from baseline to visit 4, after 28 
days of AZLI treatment or placebo. For the total score, the original trials reported an improvement of 0.8 
points (95% CI -3.1 to 4.7, p=0.68) in AIR-BX1 and 4.6 points (95% CI 1.1 to 8.2, p=0.011) in AIR-BX2. 
For individual symptoms we observed clear improvements at week 4 in daily cough, sputum production 
and sputum purulence of 20, 25.7 and 25.2% respectively (all p<0.05, table 3). There were also non-
significant improvements in congestion, but negative effect estimates for breathlessness, wheeze and chest 
pain which were not statistically significant. Table S1 online shows the results for each individual study. 
Consistent with the original trials, the effects were stronger in AIR-BX2 but were concordant in the sense 
that more patients achieved a 2 point or more improvement in individual symptoms with AZLI than with 
placebo by week 4 for congestion (p=0.015), sputum production (p=0.003) and sputum purulence (p=0.01). 
No significant differences were observed between groups for the other symptoms (table S2 online).  
 
QOLB-RSS item (pooled) Difference (95% CI) P-value 
%Change in patient 
response (95% CI) 
Q29 – Congestion 0.13 (-0.03 to 0.29)  0.110 12.3 (-3 to 25.3) 
Q30 – Daily cough 0.22 (0.08 to 0.37) 0.002* 20 (7.6 to 30.8) 
Q31 – Sputum production 0.30 (0.15 to 0.44) <0.0001* 25.7 (14.3 to 35.6) 
Q32 – Sputum purulence 0.29 (0.15 to 0.43) <0.0001* 25.2 (14.1 to 34.8) 
Q33 – Breathlessness on daily activity -0.03 (-0.17 to 0.11) 0.680 -3.1 (-18.9 to 10.7) 
Q34 - Wheeze -0.06 (-0.20 to 0.07) 0.347 -6.6 (-21.9 to 6.7) 
Q35 – Chest pain -0.04 (-0.14 to 0.05) 0.377 -4.3 (-14.5 to 5.0) 
Q36 – Breathlessness on talking 0.02 (-0.11 to 0.15) 0.779 1.8 (-11.5 to 13.6) 
Q37 – Nocturnal cough 0.04 (-0.1 to 0.18) 0.582 3.8 (-10.4 to 16.2) 
Table 3. Pooled item level response following 4 weeks of treatment with AZLI vs placebo. The difference 
represents the treatment effect between AZLI and placebo on a 4 point scale with positive values indicating 
improvement.*indicates that p-value remains statistically significant after Holm-Bonferroni correction for 
multiple comparisons.  
 
The mixed model repeated measures analysis supported the results of the week 4 analysis. Figure 1 shows 
the trajectories of individual symptoms from baseline to the end of trial. We observed improvements in 
symptoms for both AZLI and placebo treated subjects consistent with a placebo effect. A clear treatment 
benefit was evident in figures 1B, 1C and 1D consistent with improved cough, sputum production and 
sputum colour. Interestingly, inhaled antibiotic treatment appeared to provide a sustained improvement in 
cough and sputum production during the off-treatment period but sputum colour returned to baseline during 
the off-treatment period.  
 
Results of the mixed models are shown in Table S3. The best mixed model found a statistically significant 
improvement in cough and sputum with AZLI treatment throughout the study – difference 0.11 (95% CI 
0.007 to 0.23) for cough and 0.19 (95% CI 0.09 to 0.29) for sputum production, and a significant 
improvement in sputum colour on AZLI treatment at visits 3, 4 and 6 - difference 0.25 (95% CI 0.17 to 
0.33). In contrast, while on AZLI treatment there was a significant deterioration in breathlessness (-0.09; 
95% CI -0.17 to -0.002) and wheeze (-0.11; 95% CI -0.20 to -0.02), Table S3.  
We conclude that examining both the primary endpoint of week 4 and the trajectory across the study, 
inhaled aztreonam treatment improved cough, sputum production and sputum colour but resulted in 
worsening of breathlessness and wheeze. 
 
Do baseline symptoms predict treatment response?  
QOL-B RSS 
The improvement in QOL-B RSS from baseline to 4 weeks observed in the overall population was 
associated with baseline symptoms. Patients with more severe sputum production and sputum colour had a 
greater response in terms of QOL-B RSS. For sputum production, those reporting “a lot” and a “moderate 
amount” (n=309, 70.2%) had a statistically significant improvement (difference 4.82; 95% CI 1.12 to 8.53, 
p=0.011) while those reporting “a little” or “not at all” had no treatment benefit (difference -2.61; 95% CI 
-7.58 to 2.37, p=0.30). Likewise, patients with green or brownish-dark sputum (n=240, 54.5%) had an 
improvement in QOL-B RSS overall, difference 5.02 (95% CI 1.19 to 8.86, p=0.01) while those with yellow 
or clear sputum did not, difference -0.78 (95% CI -5.88 to 4.33, p=0.77) results can be seen in table S4.  
Intriguingly, patients reporting little to no wheezing (n=328, 74.5%) (difference 3.74; 95% CI 0.50 to 6.97, 
p=0.024), shortness of breath when talking (n=338, 76.8%) (difference 3.23; 95% CI 0.12 to 6.33, p=0.042 
and nocturnal cough (n=319, 72.5%) (difference 3.62; 95% CI 0.27 to 6.97, p=0.034) at baseline also 
showed statistically significant beneficial effects of treatment on overall QOL-B RSS. No other significant 
effects were observed.  
In the mixed models across all study visits the only statistically significant interaction was for sputum 
production, whereby higher sputum production at baseline was significantly associated with QOL-B RSS 
treatment response across the entire study duration difference 2.18 (95% CI 0.14 to 4.22, p=0.04), table S5 
and S6.  
 
Exacerbations 
In the original AIR-BX analysis, AZLI was associated with a non-significant shortening of time to first 
exacerbation and a higher number of exacerbations in the AZLI arm. This was speculated to be due to 
adverse effects of inhalation and bronchospasm, however, our analysis showed a phenotypical relationship 
with patients having a lower severity of congestion (n=207, 47.0%) (HR 1.69; 95% CI 1.02 to 2.8, p=0.042), 
cough (n=152, 34.5%) (HR 1.65; 95% 0.95 to 2.90, p=0.078), sputum colour (n=200, 45.5%) (HR 1.83; 
95% CI 1.02 to 3.28, p=0.042) and nocturnal cough (n=121, 27.5%) (HR 1.57; 95% CI 1.03 to 2.37, 
p=0.034) having a shorter time to first exacerbation. In contrast although not statistically significant patients 
with greater baseline wheeze (n=112, 25.5%) had a shorter time to first exacerbation (HR 1.75; 95% CI 
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Table 4. The effect of baseline symptoms on time to first exacerbation. Statistically significant effects are 
highlighted in bold, though none of these results would be regarded as statistically significant after Holm-
Bonferroni correction for multiple testing.  
 
FEV1 
No effect of treatment was observed on FEV1 when stratified by baseline symptoms (table S7). 
  
Discussion  
The aim of this post-hoc analysis was to identify which QOLB symptoms respond to treatment with inhaled 
aztreonam. We show clear differences in treatment response between different symptoms that make up the 
respiratory symptom scale of the QOL-B questionnaire. Treatment with AZLI resulted in clear 
improvements in cough, sputum production and sputum purulence while causing no effect on other 
symptoms except for shortness of breath and wheeze which were slightly worse with treatment. Given that 
these symptoms improve with therapy, it would be expected that patients with more severe cough, sputum 
production and sputum purulence at baseline would respond better to inhaled antibiotics and this was also 
what we observed. Interestingly, in the AIR-BX studies there was an increase in exacerbations in the 
treatment group which was driven by an increase in adverse events.(17) We show that patients treated with 
inhaled antibiotics that lack the above symptoms were more likely to experience exacerbations at an earlier 
timepoint.  
A series of randomized clinical trials of inhaled antibiotics in bronchiectasis have failed to demonstrate a 
significant effect on their primary endpoints. This leads to a clear need to identify which patients may 
respond to inhaled antibiotics.(19–22) An understanding of the biology of how inhaled antibiotics work 
suggests they should modify some symptoms and not others and that our current methods of identifying 
treatment response may not be optimal. 
Taken together, this study adds to our understanding of the role of inhaled antibiotics in bronchiectasis and, 
while the post-hoc nature of our study requires some caution in the interpretation of their details, the results 
are concordant with the reported pathophysiology of bronchiectasis. Bacteria and particularly Pseudomonas 
aeruginosa produce an intense neutrophil mediated inflammatory response that increases in proportion to 
airway bacterial load.(23,24) Patients with higher bacterial load and higher levels of neutrophilic 
inflammation measured using cell counts or markers of neutrophil activation such as neutrophil elastase 
(NE) have worse symptoms and a higher frequency of exacerbations.(25,26) NE in particular, is directly 
linked to symptoms by provoking secretion of mucins from bronchial epithelial cells, particularly 
MUC5AC which is a key mucin in bronchiectasis airway secretions and is linked to disease severity.(27,28) 
NE has also been reported to impair mucociliary clearance through direct effects on ciliated epithelium.(14) 
NE is released from neutrophil primary granules along with myeloperoxidase (MPO), the concentration of 
which greatly determines the green colour of purulent sputum.(23,25) Our previous work showed that 
neutrophil markers reduce in parallel with reducing bacterial load.(15,29) Therefore our results verify this 
model whereby inhaled antibiotics reduce bacterial load, which reduces neutrophilic inflammation which 
therefore reduces the stimulus for mucin secretion, improves mucociliary clearance, reducing cough and 
sputum production, and reduces sputum purulence through a fall in MPO concentration. 
We have recently shown that patients with higher bacterial load at baseline are more responsive to inhaled 
antibiotics.(18) Currently, bacterial load quantification is not routinely tested in most healthcare 
environments whereas identifying clusters of symptoms that predict response is simple and easily 
implemented into clinical practice. It is perhaps not surprising that if inhaled antibiotics reduce cough, 
sputum production and sputum purulence that patients with more of these symptoms respond better to 
treatment. Nevertheless, this is useful information for future design of trials. Despite the QOLB-RSS being 
used as the primary endpoint for the AIRBX trials, patients were not required to have any specific baseline 
symptoms for enrolment. When we analysed the baseline data we found as many as 64.8% of participants 
did not have the reported symptom at baseline (known as a ceiling effect) and therefore no measurable 
improvement is possible in that symptom. Despite the study enrolling patients with a history of Gram-
negative infection, many patients were not symptomatic and therefore may not  have been typical of the 
kind of patients being prescribed inhaled antibiotics in clinical practice.(17)  
It is interesting that wheeze and shortness of breath somewhat worsened during treatment. This is consistent 
with the recent meta-analysis of Laska et al who showed a mean reduction in FEV1 with inhaled antibiotic 
treatment across 16 trials and the results of individual studies which have shown that inhaled antibiotics are 
irritant to the epithelium and therefore can cause bronchoconstriction or bronchospasm.(9) While there has 
been a lot of focus on the number of patients withdrawing from treatment as a result of bronchospasm our 
results suggest that even in patients that persist with therapy there can be a deterioration in shortness of 
breath.  
How do these results affect our future approach to inhaled antibiotic trials? Approval of drugs by regulatory 
agencies such as the US Food and Drug administration requires demonstration that drugs improve how 
patients “feel, function or survive”. This means showing an effect on symptoms or quality of life. We 
suggest that future studies should aim to enrich for patients with a higher level of the symptoms that are 
likely to respond to inhaled antibiotics. Secondly, cough, sputum production and sputum purulence are the 
key symptoms of bronchiectasis but comprise only 1/3 of the weight of the respiratory symptom domain of 
the quality of life bronchiectasis questionnaire. A questionnaire that gives greater weight to these symptoms 
may be more relevant to inhaled antibiotic treatment. The difference in weighting as well as recall period 
may explain differences observed in the RESPIRE trials where the St Georges Respiratory Questionnaire 
improved with treatment but the QOL-B questionnaire did not.(20,21) Indeed the widespread use of inhaled 
antibiotics in clinical practice suggests that physicians and patients find them beneficial and that 
improvements in these 3 key symptoms are considered clinically important by patients.(30)  
Our post-hoc analysis of quality of life data has provided a more detailed insight to the true drug response 
experienced in the AIRBX trials and may provide an improved understanding to the ideal patient phenotype 
who should be recruited into antibiotic trials. Nevertheless, our study has important limitations. Only 81% 
of the original trial cohort was available for re-analysis, though we have previously shown that the cohorts 
of included/excluded patients had no significant differences.(18) Our post-hoc analysis is exploratory by 
definition and requires confirmation in further cohorts. In particular, we tested only one formulation of 
inhaled antibiotics in the form of aztreonam and validation with other antibiotics would be of interest. The 
effect of inhaled antibiotics on cough, sputum production and sputum purulence is mediated by the ability 
to reduce bacterial load, and the recent study by Laska et al of 16 inhaled antibiotics trials found no 
heterogeneity between aztreonam (pooled bacterial load reduction 2.6 log units 95% CI 2.1 to 3.1) and the 
other antibiotics included (pooled reduction 2.3 units 95% CI 1.2 to 3.4) in both their ability to reduce 
bacterial load and to improve symptoms (heterogeneity I2=1%).(9) This strengthens the view that these 
results will be generalizable. Only the central conclusion of the study, that inhaled antibiotics improve 
cough, sputum production and sputum colour remained statistically significant after adjustment for multiple 
comparisons. Therefore the results showing that baseline symptoms predict treatment response should be 
treated with caution as given the number of comparisons performed, some of the results may have arisen 
by chance. These are, however, not entirely independent analyses, and the number, consistency, and 
biological plausibility of our findings give confidence in their overall pattern. In the original AIR-BX 
studies a symptomatic benefit was seen in the first 4 week treatment period that was not evident during the 
second on treatment period.(17) The reasons for this are unknown but they also impacted on our analysis 
where the strength of associations with symptoms were strongest in the first 4 weeks and weaker when 
analysed over the full study duration. No specific minimum clinically important difference has been 
established for individual symptoms on the 4 point scale, and so while we found statistically significant 
differences favouring aztreonam vs placebo for cough, sputum purulence and sputum colour, further work 
is required to understand the clinical impact of these changes. Nevertheless change of 1 point on the 4 point 
scale is substantial, as it indicates a change from “a lot” to “a moderate amount”, “a little” to “not at all”, 
“often” to ”sometimes” or “sometimes” to “never” for individual symptoms to give some examples. The 
absolute changes observed in our study would generate a number needed to treat for a cough and sputum 
production of between 3 and 5 patients to achieve a 1 point change in each symptom.  
In conclusion, our results suggest aztreonam improves cough, sputum production and sputum colour but 
does not significantly affect other symptoms in bronchiectasis. Inhaled antibiotic treatment may be most 
effective in patients with daily cough and producing discoloured sputum, and clinicians may wish to avoid 
treatment in patients with significant breathlessness and wheeze. Future trials should consider enrolling 
patients with a higher burden of bronchitic symptoms and develop symptom evaluation tools which give 
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Figure 1. Trajectories of individual symptoms comparing AZLI treatment vs placebo in the full model as 
described in the statistical analysis section. Solid lines show the response in the group receiving AZLI and 
broken lines show the placebo response. 7 visits are shown; visits 1 and 2 are screening and baseline prior 
to treatment, visit 3 is 14 days into the first treatment cycle, visit 4 at 28 days (end of the first treatment 
cycle), visit 5 is at the end of the off-treatment cycle (28-days off treatment). Visit 6 is the end of the second 
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Trial QOL-B question Difference (95% CI) p-value % change in patient 
response (95% CI) 
AIRBX1 29- Congestion 
30- Cough 
31- Sputum production 
32- Sputum colour 
33- Shortness of breath 
34- Wheezing 
35- Chest pain 
36- SOB when talking 
37- nocturnal cough 
0.04 (-0.21 to 0.29) 
0.09 (-0.14 to 0.32) 
0.22 (-0.01 to 0.46) 
0.18 (-0.03 to 0.39) 
-0.01 (-0.24 to 0.22) 
-0.04 (-0.25 to 0.17) 
-0.07 (-0.19 to 0.06) 
-0.05 (-0.27 to 0.17) 










4.2 (-23.2 to 25.5) 
8.8 (-14.5 to 27.4) 
20.1 (-1.2 to 36.9) 
16.2 (-3.4 to 32.1) 
-0.9 (-26.4 to 19.5) 
-4.5 (-28.8 to 15.3) 
-6.8 (-21.1 to 5.8) 
-4.9 (-30.7 to 15.9) 
12.6 (-10.3 to 30.7) 
AIRBX2 29- Congestion 
30- Cough 
31- Sputum production 
32- Sputum colour 
33- Shortness of breath 
34- Wheezing 
35- Chest pain 
36- SOB when talking 
37- nocturnal cough 
0.20 (-0.01 to 0.41) 
0.32 (0.13 to 0.50) 
0.35 (0.18 to 0.53) 
0.37 (0.18 to 0.55) 
-0.05 (-0.23 to 0.14) 
-0.08 (-0.26 to 0.09) 
-0.02 (-0.15 to 0.11) 
0.06 (-0.10 to 0.21) 










17.8 (-1.2 to 33.3) 
27.0 (12 to 39.5) 
29.7 (16.1 to 41.1) 
30.6 (16.7 to 42.1) 
-4.8 (-26.0 to 12.8) 
-8.7 (-29.3 to 8.6) 
-2.0 (-16.2 to 10.5) 
5.4 (-10.2 to 18.8) 
-2.8 (-21.9 to 13.2) 
Table S1 – Treatment response for individual symptoms in AIRBX 1 & 2. Statistically significant effects 
are highlighted in bold.  
 
 
QOLB-RSS item AIRBX1 AIRBX2 
Pooled  
 (improved MCID) 
Pooled 
(worsening MCID) 
Q29 – Congestion 0.499 0.035 0.015 0.171 
Q30 – Daily cough - - 0.074 0.659 
Q31 – Sputum production 0.053 0.02 0.003 0.143 
Q32 – Sputum purulence 0.864 0.004 0.01 0.392 
Q33 – Breathlessness on daily 
activity - - 0.687 0.126 
Q34 – Wheeze - - 0.929 0.16 
Q35 – Chest pain - - 0.657 0.334 
Q36 – Breathlessness on talking - - 0.363 0.073 
Q37 – Nocturnal cough - - 0.327 0.27 
Table S2. Chi-squared test determining treatment effect with a MCID response following 4 weeks of 
treatment. Where a statistically significant effect was observed in the pooled data the analysis was 




Table S3- Trajectories for answers to individual questions. 
Models were separately fitted to the answers to each question. As there are only four possible answers to 
each question, uncertainties around these models’ estimates were generated by bootstrap resampling the 
data and a pragmatic and empirical approach taken to model selection. The data from the two trials was 
pooled for simplicity and because preliminary analyses identified no differences between them. Each model 
contained an intercept term and a random effect for individual. The full model for each question also 
contained four terms: short (visit 3,4,6) and long (study duration) term placebo effects, affecting both arms 
equally, and equivalent drug effects that only affected the people on AZLI. 15 sub-models were fitted, 
containing each combination of the four treatment terms. Terms were considered statistically significant 
where their 95% confidence interval from bootstrapping did not cross zero. The model for each question, 
among those for which all parameters were statistically significant, that contained the largest number of 
parameters was considered best. Where this produced multiple candidates, parameters that were significant 
in the full model, or failing that, those with the largest absolute parameter value (effect size), were favoured. 
 
 Placebo effect, affecting both arms 
equally 
Drug effect on AZLI population only 
Q model Intercept short term  
(visit 3,4,6) 
long term  
(study duration) 
short term  
(visit 3,4,6) 
long term  
(study duration) 
29 full 1.40 (1.31, 1.48) 0.06 (-0.03, 0.15) 0.20 (0.10, 0.30) 0.06 (-0.09, 0.21) -0.06 (-0.19, 0.07) 
best 1.40 (1.31, 1.48) 0.09 (0.02, 0.16) 0.17 (0.10, 0.25) - - 
30 full 1.09 (1.02, 1.15) 0.05 (-0.04, 0.13) 0.16 (0.06, 0.26) 0.06 (-0.07, 0.19) 0.14 (0.02, 0.28) 
best 1.09 (1.02, 1.15) - 0.19 (0.11, 0.27) 0.11 (0.01, 0.20) 0.11 (0.007, 0.23) 
31 full 1.00 (0.94, 1.07) 0.09 (0.01, 0.17) 0.16 (0.07, 0.24) 0.09 (-0.03, 0.21) 0.14 (0.01, 0.26) 
best 1.00 (0.94, 1.07) 0.14 (0.08, 0.20) 0.13 (0.05,0.21) - 0.19 (0.09, 0.29) 
32 full 1.39 (1.33, 1.46) -0.01 (-0.09, 0.06) 0.12 (0.04, 0.21) 0.27 (0.16, 0.39) -0.03 (-0.16, 0.09) 
best 1.39 (1.33, 1.46) - 0.11 (0.05, 0.16) 0.25 (0.17, 0.33) - 
33 full 1.48 (1.39, 1.57) 0.06 (-0.01, 0.13) 0.10 (0.02, 0.18) -0.07 (-0.17, 0.03) -0.03 (-0.14, 0.08) 
best 1.48 (1.39, 1.57) 0.07 (0.01, 0.13) 0.09 (0.02, 0.15) -0.09 (-0.17, -0.002) - 
34 full 1.98 (1.90, 2.06) 0.05 (-0.01, 0.12) 0.11 (0.03, 0.19) -0.05 (-0.15, 0.05) -0.03 (-0.13,0.08) 
best 2.01 (1.93, 2.08) 0.11 (0.06, 0.17) - -0.11 (-0.20, -0.02) 0.08 (0.01, 0.15) 
35 full 2.55 (2.48, 2.61) 0.01 (-0.03, 0.06) 0.09 (0.03, 0.16) -0.01 (-0.10, 0.07) -0.03 (-0.11, 0.05) 
best 2.55 (2.48, 2.61) - 0.08 (0.04, 0.12) - - 
36 full 2.05 (1.98, 2.13) 0.05 (-0.01,0.11) 0.04 (-0.03, 0.11) -0.03 (-0.13, 0.05) -0.02 (-0.12, 0.08) 
best 2.05 (1.98, 2.13) 0.05 (0.004, 0.10) - - - 
37 full 1.96 (1.88, 2.03) 0.05 (-0.02,0.13) 0.08 (-0.01, 0.17) 0.03 (-0.09, 0.14) -0.003 (-0.12, 0.11) 
best 1.96 (1.88, 2.03) 0.07 (0.01,0.12) 0.07 (0.01, 0.14) - - 
Table S3: Models of answers to each question. Each cell contains the parameter estimate with the 95% 
confidence interval estimated by bootstrapping.  Bold type indicates terms where the 95% CI does not 
include zero. 
 
Table S4 and S5. Impact of baseline symptoms on overall QOL-B response. 
Baseline symptom groups were associated with different responses in the overall QOL-B RSS scores 
from baseline to visit 4 as shown below in table S4.  
 
Table S4 - Effect of baseline symptoms on changes to total QOL-B RSS at week 4 
 
  
Overall effect on QOLB 
  
Symptom Effect estimate (95% CI) p-value 
Q31- sputum production   
1 - 2 (severe) 4.82 (1.12 to 8.53) 0.011 
3 - 4 (mild) -2.61 (-7.58 to 2.37) 0.305 
Q32 colour   
1 - 2 (severe) 5.02 (1.19 to 8.86) 0.01 
3 - 4 (mild) -0.78 (-5.88 to 4.33) 0.766 
Q34 Wheezing   
1 - 2 (severe) -0.66 (-8.06 to 6.74) 0.861 
3 - 4 (mild) 3.74 (0.50 to 6.97) 0.024 
Q36 SOB when talking   
1 - 2 (severe) 0.66 (-7.67 to 8.99) 0.876 
3 - 4 (mild) 3.23 (0.12 to 6.33) 0.042 
Q37 Woken due to cough     
1 - 2 (severe) -0.33 (-7.01 to 6.35) 0.923 
3 - 4 (mild) 3.62 (0.27 to 6.97) 0.034 
 
Nine sets of 194 mixed models were fitted to the data from visits 2-7 of both trials together looking at the 
effect of each question separately. These models allowed a common drift over time for all individuals, and 
potentially different long and short term treatment effects on placebo and AZLI and an interaction between 
each of these and the answer to the symptom question at baseline. The estimates for the effects of the 
baseline questions are shown in table S4 below, the other parameter values are uninteresting. In each case 
the full model contains all the parameters, the best model is the one with the lowest AICc, and the average 
is a model averaged result, that uses the AICc weight for each model. This stage was necessary because 
there would be over 1015 models if each combination of all these terms for all questions were considered.  
Q model effect of  baseline 
question answer 
interaction of baseline question answer with: 
Placebo effect, affecting both 
arms equally 
Drug effect on AZLI population 
only 
long term  
(study duration) 
short term  
(visit 3,4,6) 
long term  
(study duration) 
short term  
(visit 3,4,6) 
29 full 12.86 (0.66) -3.34 (0.74) -1.23 (0.71) 0.41 (1.08) -1.02 (1.09) 
best 12.86 (0.66) -3.17 (0.58) -1.67 (0.54) - - 
average 12.86 (0.66) -3.23 (0.63) -1.32 (0.78) -0.46 (0.83) 0.02 (0.36) 
p <0.001 <0.001 0.09 0.58 0.95 
30 full 13.74 ( 0.87) -3.95 (0.90) -0.90 (0.85) 0.01 (1.33) -1.25 (1.32) 
best 13.74 ( 0.87 -4.33 (0.62) - - -1.92 (0.87) 
average 13.74 ( 0.87 -4.17 (0.74) -0.66 (0.82) -0.02 (0.44) -0.97 (1.14) 
p <0.001 <0.001 0.42 0.96 0.39 
31 full 12.63 (0.97) -3.52 (0.99) -0.85 (0.94) 0.57 (1.43) -2.66 (1.41) 
best 12.63 (0.97) -3.67 (0.67) - - -3.07 (0.92) 
average 12.63 (0.97) -3.52 (0.78) -0.55 (0.89) 0.07 (0.56) -2.49 (1.39) 
p <0.001 <0.001 0.53 0.90 0.07 
32 full 6.90 (1.02) -2.06 (0.98) -2.23 (0.93) -2.27 (1.41) 0.13 (1.38) 
best 6.90 (1.02) -3.10 (0.74) -2.17 (0.69) - - 
average 6.86 (1.03) -2.63 (1.20) -1.90 (1.04) -0.98 (1.47) -0.43 (1.08) 
p <0.001 0.03 0.68 0.51 0.69 
33 full 11.22 (0.65) -1.24 (0.74) -1.67 (0.71) 2.42 (1.04) -1.88 (1.03) 
best 11.22 (0.65) -2.44 (0.47) - - - 
average 11.22 (0.65) -2.07 (0.83) -0.57 (0.83) -0.39 (0.96) 0.66 (1.12) 
p <0.001 0.01 0.50 0.69 0.56 
34 full 12.59 (0.79) -3.49 (0.83) -0.60 (0.80) -0.97 (1.21) -0.24 (1.20) 
best 12.59 (0.80) -4.34 (0.53) - - - 
average 12.59 (0.80) -4.05 (0.65) -0.20 (0.47) -0.16 (0.55) -0.39 (0.73) 
p <0.001 <0.001 0.68 0.77 0.59 
35 full 12.46 (1.09) -4.83 (1.19) 0.89 (1.13) 0.65 (1.57) -1.05 (1.55) 
best 12.46 (1.09) -4.29 (0.69) - - - 
average 12.46 (1.09) -4.33 (0.78) 0.11 (0.48) 0.01 (0.42) -0.07 (0.55) 
p <0.001 <0.001 0.82 0.90 0.99 
36 full 11.92 (0.83) -2.86 (0.89) 0.77 (0.85) -0.68 (1.27) 0.74 (1.26) 
best 11.92 (0.83) -3.17 (0.68) 1.11 (0.63) - - 
average 11.92 (0.83) -2.88 (0.73) 0.56 (0.72) -0.06 (0.44) 0.29 (0.71) 
p <0.001 <0.001 0.44 0.88 0.68 
37 full 12.80 (0.76) -5.01 (0.83) -0.56 (0.79) 2.40 (1.17) -0.61 (1.16) 
best 12.80 (0.76) -4.84 (0.76) -0.84 (0.58) 2.02 (0.92) - 
average 12.80 (0.76) -4.74 (0.86) -0.37 (0.61) 1.29 (1.35) -0.15 (0.72) 
p <0.001 <0.001 0.54 0.34 0.83 
total 
score 
full 0.93 (0.03) -0.26 (0.04) -0.06 (0.04) -0.01 (0.06) -0.02 (0.06) 
best 0.93 (0.03) -0.26 (0.03) -0.07 (0.03) - - 
average 0.93 (0.03) -0.27 (0.03) -0.05 (0.04) -0.002 (0.017) -0.02 (0.04) 
p <0.001 <0.001 0.23 0.92 0.63 
 
Table S5: Parameter estimates in models of the effect of each question’s answer at visit 1 on QOLB-RSS 
scores at visits 2-7. Each full model contained the terms shown plus separate short and long term effects of 
treatment, allowing these to be different for placebo and AZLI. The data from the two trials was combined, 
and an intercept plus a single common drift term included along with individual as a random effect. 
 
The 25 question-based parameters that had p-values less than 0.5 were put into a model along with the four 
treatment terms and the models nested within it refitted. At this stage, all the individual question main 
effects had values close to 3, so they were replaced with the total score at visit 1, and the model fitting was 
redone. Separate terms were included for the interaction between being on the trial and the answer to each 
question, as well as with the total score at baseline. The main effects for the baseline score and the short 
term (visit=3,4,6) and longer term (duration of study) placebo effects were required to be in all of the 98,304 
models. Table S5 shows the results: 
parameter estimate (SE) in models: p 
full (A) best (B) averaged 
 Intercept 4.75 (1.62) 4.76 (1.58) 4.88 (1.62) 0.003 
 drift 0.015 (0.009) 0.015 (0.009) 0.009 (0.01) 0.35 




main (placebo) effect 21.12 (2.42) 20.18 (1.97) 20.5 (2.32) <0.0001 
drug effect -0.09 (0.98) - -0.02 (0.51) 0.97 
interaction with Q29 -0.12 (0.67) - -0.16 (0.45) 0.73 
interaction with Q30 -1.51 (0.63) -1.63 (0.54) -1.48 (0.69) 0.03 
interaction with Q31 -0.43 (0.68) - -0.18 (0.48) 0.71 
interaction with Q32 -3.42 (0.52) -3.39 (0.48) -3.37 (0.49) <0.0001 
interaction with Q33 0.43 (0.59) - 0.10 (0.31) 0.75 
interaction with Q34 -2.31 (0.55) -2.11 (0.49) -2.20 (0.52) <0.0001 
interaction with Q35 -1.63 (0.63) -1.53 (0.60) -1.40 (0.74) 0.06 
interaction with Q36 -0.25 (0.57) - -0.02 (0.30) 0.94 







Main (placebo) effect 2.70 (2.17) 3.91 (0.94) 3.44 (1.57) 0.03 
drug effect 4.69 (1.39) 4.64 (1.14) 4.48 (1.37) 0.001 
interaction with total 
baseline score 
0.04 (0.08) - 0.003 (0.034) 0.93 
interaction with Q29 -1.70 (0.87) -1.44 (0.45) -1.37 (0.72) 0.06 
interaction with Q33 -0.25 (0.74) - 0.05 (0.31) 0.88 
interaction with Q37 -0.28 (0.83) - -0.05 (0.43) 0.90 
interaction with Q31 
and on AZLI 
-2.31 (0.93) -2.36 (0.83) -2.18 (1.04) 0.04 
      
 AICc 20799.0 20784.6   
 ΔAICc +14.4 0   
 AICc weight 0.00002 0.03   
 
Table S6: parameters in models of total score that allow effects from answers to individual questions at 
visit 1. The baseline QOL-B score is out of 100, while each question is scored 1-4, complicating the 
comparison of their effect sizes. 
The intercepts for the models of different questions differ, reflecting the pattern of baseline symptoms 
among the participants, but the placebo estimated effects are remarkably similar. This suggests that such 
reported improvements were distributed across the range of symptoms. There seems to be more variability 
in the reported effects of AZLI itself, with answers to some questions (30,31,32,34) being more affected 







Table S7- Effect of baseline symptoms on changes in FEV1 at week 4 
 
 
  Overall effect on FEV1 
Symptom 
Effect estimate (95% CI) p-value 
Overall effect -0.01 (-0.12 to 0.09) 0.85 
Q29- congestion      
1 -0.113 (-0.32 to 0.09) 0.277 
2 0.036 (-0.14 to 0.22) 0.696 
3 0.035 (-0.19 to 0.26) 0.754 
4 -0.096 (-0.28 to 0.08 0.296 
Q30- cough     
1 -0.095 (-0.26 to 0.07) 0.266 
2 -0.072 (-0.27 to 0.13) 0.483 
3 0.083 (-0.09 to 0.25) 0.339 
4 -0.147 (-0.46 to 0.17) 0.348 
Q31- sputum production     
1 -0.156 (-0.33 to 0.02) 0.082 
2 0.11 (-0.16 to 0.18) 0.902 
3 0.114 (-0.10 to 0.33) 0.289 
4 0.036 (-0.56 to 0.64) 0.906 
Q32 colour     
1 -0.274 (-0.46 to 0.02) 0.07 
2 0.108 (-0.05 to 0.27) 0.181 
3 -0.085 (-0.28 to 0.11) 0.382 
4 0.022 (-0.39 to 0.44) 0.916 
Q33 daily activity     
1 0.038 (-0.18 to 0.25) 0.729 
2 -0.049 (-0.25 to 0.16) 0.637 
3 0.018 (-0.16 to 0.20) 0.842 
4 -0.098 (-0.35 to 0.15) 0.437 
Q34 Wheezing     
1 -0.029 (-0.51 to 0.45) 0.904 
2 -0.066 (-0.25 to 0.12) 0.484 
3 0.063 (-0.09 to 0.22) 0.419 
4 -0.065 (-0.27 to 0.14) 0.532 
Q35 chest pain     
1 -0.332 (-1.1 to 0.44) 0.396 
2 0.164 (-0.08 to 0.41) 0.195 
3 0.105 (-0.10 to 0.31) 0.327 
4 -0.064 (-0.19 to 0.07) 0.331 
Q36 SOB when talking     
1 0.085 (-0.30 to 0.47) 0.661 
2 -0.018 (-0.28 to 0.25) 0.896 
3 -0.032 (-0.19 to 0.13) 0.69 
4 -0.004 (-0.19 to 0.18) 0.968 
Q37 Woken due to cough     
1 0.338 (-0.01 to 0.68) 0.053 
2 0.046 (-0.18 to 0.27) 0.69 
3 0.03 (-0.16 to 0.16) 0.968 
4 -0.124 (-0.32 to 0.07) 0.213 
 
Table S7. No effect of AZLI on FEV1 change from baseline to week 4 regardless of baseline symptoms. 
As no effect was seen for any individual symptoms no further analysis was performed.   
 
 
 
